Jim Sang

1.7k citations

21 papers · 1.2k indexed · h-index 16

Impact in

Molecular Biology top 10%
- Heat shock proteins research
- ATP Synthase and ATPases Research
- Cancer therapeutics and mechanisms
Aging top 10%

Papers in

Molecular Biology 20
- Heat shock proteins research 18
- ATP Synthase and ATPases Research 9
- Cancer therapeutics and mechanisms 3
- Insect Resistance and Genetics 1
Computational Theory and Mathematics 4
- Computational Drug Discovery Methods 4

Co-authors: David A. Proia Donald L. Smith Suqin He Manuel Sequeira Chaohua Zhang Jaime Acquaviva Richard C. Bates Kevin P. Foley
Journals: Molecular Cancer Therapeutics (5 papers)Clinical Cancer Research (3 papers)Investigational New Drugs (3 papers)Molecular Cancer Research (2 papers)Journal of Pharmacology and Experimental Therapeutics (1 paper)
Partner nations: United States United Kingdom

In The Last Decade

Jim Sang

21 papers receiving 1.2k citations

Peers

Countries citing papers authored by Jim Sang

Since Specialization

Citations

This map shows the geographic impact of Jim Sang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jim Sang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jim Sang more than expected).

Fields of papers citing papers by Jim Sang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jim Sang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jim Sang. The network helps show where Jim Sang may publish in the future.

Co-authors

The 25 scholars most cited alongside Jim Sang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jim Sang Line = papers co-authored together Jim Sang links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	HSP90 Inhibitor–SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors Molecular Cancer Therapeutics ·David A. Proia, Donald L. Smith, Junyi Zhang, John-Paul Jimenez, Jim Sang, Luisa Shin Ogawa, Manuel Sequeira, Jaime Acquaviva, Suqin He, Chaohua Zhang, Vladimir Khazak, Igor Astsaturov, Takayo Inoue, Noriaki Tatsuta, Sami Osman, Richard C. Bates, Dinesh Chimmanamada, Weiwen Ying	2015	29
2	FGFR3 Translocations in Bladder Cancer: Differential Sensitivity to HSP90 Inhibition Based on Drug Metabolism Molecular Cancer Research ·Jaime Acquaviva, Suqin He, Chaohua Zhang, John-Paul Jimenez, Masazumi Nagai, Jim Sang, Manuel Sequeira, Donald L. Smith, Luisa Shin Ogawa, Takayo Inoue, Noriaki Tatsuta, Margaret A. Knowles, Richard C. Bates, David A. Proia	2014	57
3	mTOR Inhibition Potentiates HSP90 Inhibitor Activity via Cessation of HSP Synthesis Molecular Cancer Research ·Jaime Acquaviva, Suqin He, Jim Sang, Donald L. Smith, Manuel Sequeira, Chaohua Zhang, Richard C. Bates, David A. Proia	2014	40
4	Overcoming Acquired BRAF Inhibitor Resistance in Melanoma via Targeted Inhibition of Hsp90 with Ganetespib Molecular Cancer Therapeutics ·Jaime Acquaviva, Donald L. Smith, John-Paul Jimenez, Chaohua Zhang, Manuel Sequeira, Suqin He, Jim Sang, Richard C. Bates, David A. Proia	2014	79
5	The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer Investigational New Drugs ·Suqin He, Donald L. Smith, Manuel Sequeira, Jim Sang, Richard C. Bates, David A. Proia	2014	57
6	The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer Targeted Oncology ·Donald L. Smith, Jaime Acquaviva, Manuel Sequeira, John-Paul Jimenez, Chaohua Zhang, Jim Sang, Richard C. Bates, David A. Proia	2014	31
7	Preclinical Activity Profile and Therapeutic Efficacy of the HSP90 Inhibitor Ganetespib in Triple-Negative Breast Cancer Clinical Cancer Research ·David A. Proia, Chaohua Zhang, Manuel Sequeira, John-Paul Jimenez, Suqin He, Neil L. Spector, Geoffrey I. Shapiro, Sara M. Tolaney, Masazumi Nagai, Jaime Acquaviva, Donald L. Smith, Jim Sang, Richard C. Bates, Iman El‐Hariry	2013	53
8	Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer Cancer Discovery ·Jim Sang, Jaime Acquaviva, Julie C. Friedland, Donald L. Smith, Manuel Sequeira, Chaohua Zhang, Qin Jiang, Liquan Xue, Christine M. Lovly, Laura Aillaud, Alice T. Shaw, Robert C. Doebele, Suqin He, Richard C. Bates, D. Ross Camidge, Stephan W. Morris, Iman El‐Hariry, David A. Proia	2013	174
9	Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes Investigational New Drugs ·Julie C. Friedland, Donald L. Smith, Jim Sang, Jaime Acquaviva, Suqin He, Chaohua Zhang, David A. Proia	2013	46
10	Abstract 1038: Inhibition of mTOR enhances the activity of HSP90 inhibitors in part through cessation of heat shock protein synthesis. Cancer Research ·Suqin He, Jaime Acquaviva, Julie C. Friedland, Jim Sang, Donald L. Smith, Manuel Sequeira, Chaohua Zhang, David A. Proia	2013	1
11	Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non–Small Cell Lung Cancer Clinical Cancer Research ·Takeshi Shimamura, Samanthi A. Perera, Kevin P. Foley, Jim Sang, Scott J. Rodig, Takayo Inoue, Liang Chen, Danan Li, Julián Carretero, Yuchen Li, Papiya Sinha, Christopher D. Carey, Christa L. Borgman, John-Paul Jimenez, Matthew Meyerson, Weiwen Ying, James Barsoum, Kwok‐Kin Wong, Geoffrey I. Shapiro	2012	131
12	Targeting KRAS-Mutant Non–Small Cell Lung Cancer with the Hsp90 Inhibitor Ganetespib Molecular Cancer Therapeutics ·Jaime Acquaviva, Donald L. Smith, Jim Sang, Julie C. Friedland, Suqin He, Manuel Sequeira, Chaohua Zhang, Yumiko Wada, David A. Proia	2012	83
13	Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression International Journal of Oncology ·Suqin He, Chaohua Zhang, Ayesha A. Shafi, Manuel Sequeira, Jaime Acquaviva, Julie C. Friedland, Jim Sang, Donald L. Smith, Nancy L. Weigel, Yumiko Wada, David A. Proia	2012	50
14	The Vascular Disrupting Agent STA-9584 Exhibits Potent Antitumor Activity by Selectively Targeting Microvasculature at Both the Center and Periphery of Tumors Journal of Pharmacology and Experimental Therapeutics ·Kevin P. Foley, Dan Zhou, Seak Kang, Yaming Wu, Mei Zhang, Jun Jiang, Hao Li, Jim Sang, Yves Schwander, F. W. Riegels, Xuemei Zhang, James Barsoum, Andrew J. Sonderfan	2012	8
15	Preclinical activity of the Hsp90 inhibitor, ganetespib, in ALK- and ROS1-driven cancers. Journal of Clinical Oncology ·David A. Proia, Jaime Acquaviva, Qin Jiang, Liquan Xue, Donald L. Smith, Julie C. Friedland, Suqin He, Jim Sang, Stephan W. Morris, Yumiko Wada	2012	3
16	Abstract B1: Targeting KRAS mutant NSCLC with the Hsp90 inhibitor ganetespib Clinical Cancer Research ·Jaime Acquaviva, G. Strevelar, Jim Sang, Yumiko Wada, David A. Proia	2012	1
17	Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy Molecular Cancer Therapeutics ·Weiwen Ying, Zhenjian Du, Lijun Sun, Kevin P. Foley, David A. Proia, Ronald K. Blackman, Dan Zhou, Takayo Inoue, Noriaki Tatsuta, Jim Sang, Shuxia Ye, E. Alvarez, Luisa Shin Ogawa, Yumiko Wada, James Barsoum, Keizo Koya	2011	181
18	Multifaceted Intervention by the Hsp90 Inhibitor Ganetespib (STA-9090) in Cancer Cells with Activated JAK/STAT Signaling PLoS ONE ·David A. Proia, Kevin P. Foley, Yves Schwander, Jim Sang, G. Strevelar, Richard C. Bates, Yuan Liu, Alex Rosenberg, Dan Zhou, Keizo Koya, James Barsoum, Ronald K. Blackman	2011	65
19	Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias Blood ·Hima Bansal, Sanjay Bansal, Manjeet K. Rao, Kevin P. Foley, Jim Sang, David A. Proia, Ronald K. Blackman, Weiwen Ying, James Barsoum, Maria R. Baer, Kevin R. Kelly, Ronan Swords, Gail E. Tomlinson, Minoo Battiwalla, Francis J. Giles, Kelvin P. Lee, Swaminathan P. Iyer	2010	41
20	The oxidative stress inducer STA-4783 enhances the in vivo efficacy of multiple anti-cancer therapies in mouse tumor models Molecular Cancer Therapeutics ·Kevin P. Foley, John Bertin, GU Wan-dan, Amy Hutchings, Takayo Inoue, Jessica R. Kirshner, Timothy Korbut, Long Li, Robert Mihalek, Patricia E. Rao, Jim Sang, G. Strevelar, Noriaki Tatsuta, Chaohua Zhang, Dan Zhou, James Barsoum	2007	4

About Jim Sang

Jim Sang is a scholar working on Molecular Biology, Computational Theory and Mathematics, Immunology, Oncology and Organic Chemistry, having authored 21 papers that have together received 1.2k indexed citations. Recurring topics across this work include Heat shock proteins research (18 papers), ATP Synthase and ATPases Research (9 papers), Computational Drug Discovery Methods (4 papers), Toxin Mechanisms and Immunotoxins (4 papers), Cancer therapeutics and mechanisms (3 papers), Click Chemistry and Applications (2 papers), Lung Cancer Treatments and Mutations (2 papers) and Insect Resistance and Genetics (1 paper). The work is most often cited by research in Molecular Biology (1.0k citations), Aging (20 citations), Oncology (289 citations), Physical and Theoretical Chemistry (78 citations) and Pulmonary and Respiratory Medicine (274 citations). Jim Sang has collaborated with scholars based in United States and United Kingdom. Frequent co-authors include David A. Proia, Donald L. Smith, Suqin He, Manuel Sequeira, Chaohua Zhang, Jaime Acquaviva, Richard C. Bates, Kevin P. Foley, Yumiko Wada and Julie C. Friedland. Their work appears in journals such as Molecular Cancer Therapeutics, Clinical Cancer Research, Investigational New Drugs, Molecular Cancer Research and Journal of Pharmacology and Experimental Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact